AU · rank #6 · 2026-10-21
SHL
XETRA · EUR · $52.07B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.853 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 6 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $45.40 | +9.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +24.95% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.0% |
| 52w high | $48.54 |
| Market cap (USD) | $52.07B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Siemens Healthineers (SHL@XETRA) is a diversified medical-device group spanning Imaging, Precision Therapy, Diagnostics and Advanced Therapies, with Precision Therapy and angiography driving growth while Diagnostics remains under China and platform-transition pressure.
Rationale
The stock still screens well for analyst_upside because the name has modest but real upside to consensus, favorable recent EPS revisions and high analyst agreement, while management’s raised FY2026 EPS guide supports the Street’s earnings trajectory despite softer revenue.
Material risks
- 1Diagnostics is a structural drag from China volume-based procurement and customer migration to a new lab platform, which can keep estimates and sentiment unstable.
- 2The general-ultrasound franchise is being de-emphasized and commoditized, with SHL exiting four product families, increasing the risk of share loss and lower long-term pricing power.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.